Separately, HC Wainwright reduced their price target on shares of Caladrius Biosciences from $8.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, March 23rd.
CLBS stock opened at $0.46 on Friday. Caladrius Biosciences has a 12 month low of $0.40 and a 12 month high of $1.68. The company has a 50-day moving average price of $0.62 and a 200 day moving average price of $0.78. The stock has a market cap of $27.93 million, a PE ratio of -1.15 and a beta of 1.10.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC boosted its holdings in shares of Caladrius Biosciences by 239.4% in the 3rd quarter. Barclays PLC now owns 21,103 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 14,885 shares during the last quarter. Two Sigma Securities LLC acquired a new position in Caladrius Biosciences during the third quarter worth $33,000. Alterna Wealth Management Inc. acquired a new position in Caladrius Biosciences during the fourth quarter worth $61,000. Goldman Sachs Group Inc. acquired a new stake in shares of Caladrius Biosciences in the second quarter valued at about $87,000. Finally, Millennium Management LLC raised its position in shares of Caladrius Biosciences by 46.2% in the second quarter. Millennium Management LLC now owns 64,903 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 20,498 shares during the last quarter. Hedge funds and other institutional investors own 18.76% of the company’s stock.
Caladrius Biosciences Company Profile (Get Rating)
Caladrius Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.
- Get a free copy of the StockNews.com research report on Caladrius Biosciences (CLBS)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.